Dementia is a clinical syndrome that is the result of distinct underlying pathologies including Alzheimer's disease (AD). Despite more than two decades of research on prevention and treatment of dementia and aging-related cognitive decline, highly effective preventive and therapeutic strategies remain elusive. Many features of dementia render it especially challenging. Indeed development of disease occurs insidiously over the course of years or decade. In addition, the causes of dementia and determinants of its severity are likely multi-factorial. To overcome these challenges and better understand the causes and course of AD and related disorders, long term follow-up studies of persons at high risk of dementia are required including multidimensional and harmonized assessment of risk factors, phenotypes (cognition, neuropsychiatric symptoms, physical health, self rated health) and endophenotypes (blood markers, genetic markers, neuroimaging markers). This project proposes an extension of the follow-up of Memento participants over 5 to 10 years with of focus on cognitive outcomes and comorbidities.
Study Type
OBSERVATIONAL
Enrollment
1,028
CHU d'Amiens
Amiens, France
AP-HP - CHU Avicenne
Bobigny, France
CHU de Bordeaux - Pellegrin
Bordeaux, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
Hôpitaux Civils de Colmar
Colmar, France
CHU de Dijon
Dijon, France
CHU de Grenoble
Grenoble, France
CHU de Lille
Lille, France
AP-HM
Marseille, France
CHU de Montpellier
Montpellier, France
...and 16 more locations
Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)
Time frame: Each 12 months from baseline for 5 years
Mortality
Time frame: Each 12 months from baseline for 5 years
Loss of autonomy based on functional activity assessment
Time frame: Each 12 months from baseline for 5 years
Rate of cognitive decline based on change in cognitive performances
Time frame: Each 12 months from baseline for 5 years
Incidence of neurovascular and cardiovascular events (Stroke and Coronary events)
Time frame: Each 12 months from baseline for 5 years
Quality of life: EQ-5D (EUROQOL)
EQ-5D (EUROQOL) questionnaire Subscales: VAS patient's self-rated health (0=worst, 100=best), mobility, self-care, usual activities, pain/discomfort and anxiety/depression (rated as no problems, slight problems, moderate problems, severe problems and extreme problems)
Time frame: Each 12 months from baseline for 5 years
Incidence of prodromal AD (Pre-symptomatic dementia)
Time frame: Each 12 months from baseline for 5 years
Incidence of institutionalization
Time frame: Each 12 months from baseline for 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.